October 23, 2020
In a presentation during the 27th Annual Prostate Cancer Foundation Scientific Retreat, W. Kevin Kelly, DO, explained the potential of this novel agent and its development progress.
October 23, 2020
The bispecific T‐cell engager, AMG 160, demonstrated a manageable safety profile and preliminary evidence of efficacy in heavily pretreated patients with metastatic castration-resistant prostate cancer in a 2-part, phase 1 open-label study.
October 23, 2020
The combination of ipatasertib and abiraterone acetate achieved a significantly superior radiographic progression-free survival and demonstrated anti-tumor activity compared with placebo and abiraterone in patients with metastatic castration resistant prostate cancer with PTEN loss, according to results from the phase 3 IPATential150 clinical trial.
October 23, 2020
Naomi Haas, MD, discusses several areas of interest for the treatment of patients with prostate cancer that are utilizing PSMA, including bispecific T-cell engager antibodies, chimeric antigen receptor T cells, and the lutetium studies.
October 22, 2020
A novel tubulin inhibitor VERU-111 has demonstrated promising early antitumor activity and tolerability in men with metastatic castration-resistant prostate cancer who have failed prior androgen receptor therapy, according to the results of a phase 1b/2 study.
October 22, 2020
Paul Boutros, PhD, MBA, discusses the reasons why some patients with prostate cancer have more aggressive disease than others.
October 22, 2020
Split-dosing of BXCL701 at 0.6 mg per day is a supported dosing strategy for the agent in combination with pembrolizumab as treatment of patients with metastatic castration-resistant prostate cancer, according to phase 1b/2 study results.
October 22, 2020
In a phase 2 trial, onvansertib, a polo-like kinase 1 inhibitor, combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer who have early abiraterone resistance, demonstrated a decent safety profile across 3 dosing schedules and efficacy in the evaluable arms.